[go: up one dir, main page]

Talele, 2020 - Google Patents

Acetylene group, friend or foe in medicinal chemistry

Talele, 2020

Document ID
945400731188030469
Author
Talele T
Publication year
Publication venue
Journal of medicinal chemistry

External Links

Snippet

The use of an acetylene (ethynyl) group in medicinal chemistry coincides with the launch of the Journal of Medicinal Chemistry in 1959. Since then, the acetylene group has been broadly exploited in drug discovery and development. As a result, it has become recognized …
Continue reading at pubs.acs.org (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom

Similar Documents

Publication Publication Date Title
Talele Acetylene group, friend or foe in medicinal chemistry
Hillebrand et al. Emerging and re-emerging warheads for targeted covalent inhibitors: an update
Gehringer et al. Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology
Bemis et al. Unraveling the role of linker design in proteolysis targeting chimeras: Miniperspective
Dai et al. Tranylcypromine based lysine-specific demethylase 1 inhibitor: summary and perspective
Dölle et al. Design, synthesis, and evaluation of WD-repeat-containing protein 5 (WDR5) degraders
Ray et al. New electrophiles and strategies for mechanism-based and targeted covalent inhibitor design
Li et al. Advancing strategies for proteolysis-targeting chimera design
Talele The “cyclopropyl fragment” is a versatile player that frequently appears in preclinical/clinical drug molecules
Meanwell The influence of bioisosteres in drug design: tactical applications to address developability problems
Shen et al. Discovery of a potent, selective, and cell-active dual inhibitor of protein arginine methyltransferase 4 and protein arginine methyltransferase 6
Zimmermann et al. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site
Bhela et al. A versatile and sustainable multicomponent platform for the synthesis of protein degraders: proof-of-concept application to BRD4-degrading PROTACs
Lazzara et al. Isoquinoline Kelch-like ECH-associated protein 1-nuclear factor (erythroid-derived 2)-like 2 (KEAP1-NRF2) inhibitors with high metabolic stability
Bosc et al. Kinetic target-guided synthesis: reaching the age of maturity: miniperspective
Allimuthu et al. 2-Chloropropionamide as a low-reactivity electrophile for irreversible small-molecule probe identification
Amin et al. Structure–activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: Reality behind anticancer drug discovery
Wodtke et al. N ε-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure–Activity Relationships, and Pharmacokinetic Profiling
Li et al. Ynamide electrophile for the profiling of ligandable carboxyl residues in live cells and the development of new covalent inhibitors
Horton et al. Structure-based engineering of irreversible inhibitors against histone lysine demethylase KDM5A
KR101535319B1 (en) Small molecule modulators of epigenetic regulation and their therapeutic applications
Hamilton et al. Discovery of IACS-9779 and IACS-70465 as potent inhibitors targeting indoleamine 2, 3-dioxygenase 1 (IDO1) apoenzyme
Cleghorn et al. Discovery of indoline-2-carboxamide derivatives as a new class of brain-penetrant inhibitors of Trypanosoma brucei
Yu et al. Discovery of potent and selective WDR5 proteolysis targeting chimeras as potential therapeutics for pancreatic cancer
Shergalis et al. Characterization of aminobenzylphenols as protein disulfide isomerase inhibitors in glioblastoma cell lines